A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Bill 118 s 4905, also known as the Pediatric Cancer Targeted Therapy Act, aims to make important changes to the Federal Food, Drug, and Cosmetic Act in order to improve the investigation and treatment of pediatric cancer. The bill specifically focuses on the use of molecularly targeted therapies, which are treatments that target specific molecules within cancer cells to stop the growth and spread of the disease.

One of the key provisions of the bill is to encourage the development and testing of molecularly targeted therapies for pediatric cancer. This includes providing incentives for pharmaceutical companies to conduct clinical trials specifically focused on pediatric patients. By doing so, the bill aims to increase the availability of effective treatments for children with cancer.

Additionally, the bill seeks to improve the coordination and communication between the Food and Drug Administration (FDA), National Institutes of Health (NIH), and other relevant agencies when it comes to pediatric cancer research. This will help ensure that promising treatments are identified and brought to market in a timely manner. Overall, the Pediatric Cancer Targeted Therapy Act is a bipartisan effort to address the unique challenges faced by children with cancer and to improve their access to cutting-edge treatments. By focusing on molecularly targeted therapies and promoting collaboration among key stakeholders, the bill has the potential to make a significant impact on the lives of pediatric cancer patients and their families.